Osimertinib (AZD9291) and CNS Response in Two Radiotherapy-Naïve Patients with EGFR-Mutant and T790M-Positive Advanced Non-Small Cell Lung Cancer

Clinical Drug Investigation

Volumn 36, Issue 8, 2016, Pages 683-686

  Ricciuti, Biagio ^a   Chiari, Rita ^a   Chiarini, Pietro ^a   Crinò, Lucio ^a   Maiettini, Daniele ^b   Ludovini, Vienna ^a   Metro, Giulio ^a  

^a SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; OSIMERTINIB; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR;

ADVANCED CANCER; AGED; ARTICLE; BONE METASTASIS; BRAIN DAMAGE; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CASE REPORT; CENTRAL NERVOUS SYSTEM METASTASIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; MALE; MEDICAL HISTORY; NEUROIMAGING; NON SMALL CELL LUNG CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SMOKING; TREATMENT DURATION; TREATMENT RESPONSE; BRAIN; CARCINOMA, NON-SMALL-CELL LUNG; CENTRAL NERVOUS SYSTEM NEOPLASMS; DIAGNOSTIC IMAGING; DRUG RESISTANCE; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM METASTASIS; PATHOLOGY; SECONDARY; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; BRAIN; CARCINOMA, NON-SMALL-CELL LUNG; CENTRAL NERVOUS SYSTEM NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PIPERAZINES; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84968648485     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-016-0411-1     Document Type: Article

References (8)

1. Metro G, Crinò L. Advances on EGFR mutation for lung cancer. Transl Lung Cancer Res. 2012;1(1):5–13.
2. Metro G, Chiari R, Ricciuti B, et al. Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer. Expert Opin Pharmacother. 2015;16(17):2601–13.
3. Jänne PA, Chih-Hsin J, Kim D-W, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372(18):1689–99.
4. Mitsudomi T, Tsai CM, Shepherd FA, et al. AZD9291 in pre-treated T790M positive advanced NSCLC: AURA2 phase II study [abstract]. J Thorac Oncol. 2015;10(9 Suppl 2):S320.
5. Jamal-Hanjani M, Spicer J. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain. Clin Cancer Res. 2012;18:938–44.
6. Ballard P, Yang Z, Cross D, et al. Preclinical activity of AZD9291 in EGFR-mutant NSCLC brain metastases [abstract]. J Thorac Oncol. 2015;10(9 Suppl 2):S300.
7. Ahn MJ, Tsai CM, Yang JCH, et al. AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: data from phase II studies. Eur J Cancer. 2015;51(Suppl 3):S625–6.
8. Weickhardt AJ, Scheier B, Burke JM, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol. 2012;7:1807–14.